Patients' and Health Professionals' Attitudes and Perceptions Towards the Initiation of Preventive Drugs for Primary Prevention of Cardiovascular Disease: Protocol for a Systematic Review of Qualitative Studies

Overview

Journal BMJ Open

Specialty General Medicine

Date 2019 Apr 13

PMID 30975677

Citations 2

Authors

Olla Qadi

Tom Marshall

Nicola Adderley

Danai Bem

Affiliations

Soon will be listed here.

Abstract

Introduction: Lipid-lowering drugs and antihypertensive agents can be prescribed for the primary prevention of cardiovascular disease. In some cases, patients eligible for primary prevention of cardiovascular disease according to the European guidelines are not always started on preventive drugs. Existing research explores the attitudes of health professionals and patients towards cardiovascular preventive drugs but does not always differentiate between the attitudes towards drug initiation for primary or secondary prevention. We aim to systematically review qualitative studies assessing health professionals' and patients' attitudes and perceptions towards drug initiation for primary prevention of cardiovascular disease.

Methods And Analysis: MEDLINE, MEDLINE In Process, EMBASE, PsycINFO, CINAHL, Applied Social Sciences Index and Abstracts, Conference Proceedings Citation Index (Web of Science), Healthcare Management Information Consortium, and Open Grey will be searched without restrictions on date or language of publication. Searches will be limited to studies of qualitative design, standalone or in the context of a mixed-method design, focusing on cardiovascular drug initiation for primary prevention. The primary outcome is the attitudes of health professionals and patients towards drug initiation for primary prevention of cardiovascular disease. Two reviewers will independently carry out the study selection, data extraction and quality assessment. The Critical Appraisal Skills Programme Qualitative Research Checklist will be used to assess the quality of included studies. The findings will be analysed using Thomas and Harden's thematic synthesis approach.

Ethics And Dissemination: This systematic review does not require ethical approval as primary data will not be collected. The results of the study will be published in a peer-reviewed journal and presented at relevant conferences.

Prospero Registration Number: CRD42018095346.

Citing Articles

Patients' and health professionals' attitudes and perceptions towards the initiation of preventive drugs for primary prevention of cardiovascular disease: a systematic review of qualitative studies.

Qadi O, Lufumpa N, Adderley N, Bem D, Marshall T, Kokab F BJGP Open. 2020; 4(5).

PMID: 33082157 PMC: 7880193. DOI: 10.3399/bjgpopen20X101087.

Primary Prevention of Cardiovascular Risk in Lithuania-Results from EUROASPIRE V Survey.

Urbonas G, Venceviciene L, Valius L, Krivickiene I, Petrauskas L, Lazarenkiene G Medicina (Kaunas). 2020; 56(3).

PMID: 32197516 PMC: 7143447. DOI: 10.3390/medicina56030134.

References

Homer K, Boomla K, Hull S, Dostal I, Mathur R, Robson J . Statin prescribing for primary prevention of cardiovascular disease: a cross-sectional, observational study. Br J Gen Pract. 2015; 65(637):e538-44. PMC: 4513742. DOI: 10.3399/bjgp15X686113. View

Taylor F, Huffman M, Macedo A, Moore T, Burke M, Davey Smith G . Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; (1):CD004816. PMC: 6481400. DOI: 10.1002/14651858.CD004816.pub5. View

Baker R, Wilson A, Nockels K, Agarwal S, Modi P, Bankart J . Levels of detection of hypertension in primary medical care and interventions to improve detection: a systematic review of the evidence since 2000. BMJ Open. 2018; 8(3):e019965. PMC: 5875641. DOI: 10.1136/bmjopen-2017-019965. View

Cooke A, Smith D, Booth A . Beyond PICO: the SPIDER tool for qualitative evidence synthesis. Qual Health Res. 2012; 22(10):1435-43. DOI: 10.1177/1049732312452938. View

Fleetcroft R, Schofield P, Ashworth M . Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis. BMC Health Serv Res. 2014; 14:414. PMC: 4263070. DOI: 10.1186/1472-6963-14-414. View

Turner G, Calvert M, Feltham M, Ryan R, Fitzmaurice D, Cheng K . Under-prescribing of Prevention Drugs and Primary Prevention of Stroke and Transient Ischaemic Attack in UK General Practice: A Retrospective Analysis. PLoS Med. 2016; 13(11):e1002169. PMC: 5112771. DOI: 10.1371/journal.pmed.1002169. View

Chou R, Dana T, Blazina I, Daeges M, Jeanne T . Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2016; 316(19):2008-2024. DOI: 10.1001/jama.2015.15629. View

Kedward J, Dakin L . A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care. Br J Gen Pract. 2004; 53(494):684-9. PMC: 1314690. View

Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Atherosclerosis. 2016; 252:207-274. DOI: 10.1016/j.atherosclerosis.2016.05.037. View

10.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

11.

Tong A, Flemming K, Mcinnes E, Oliver S, Craig J . Enhancing transparency in reporting the synthesis of qualitative research: ENTREQ. BMC Med Res Methodol. 2012; 12:181. PMC: 3552766. DOI: 10.1186/1471-2288-12-181. View

12.

Huffman M, Xavier D, Perel P . Uses of polypills for cardiovascular disease and evidence to date. Lancet. 2017; 389(10073):1055-1065. DOI: 10.1016/S0140-6736(17)30553-6. View

13.

Carlsen B, Glenton C, Pope C . Thou shalt versus thou shalt not: a meta-synthesis of GPs' attitudes to clinical practice guidelines. Br J Gen Pract. 2008; 57(545):971-8. PMC: 2084137. DOI: 10.3399/096016407782604820. View

14.

Carlsen B, Norheim O . "What lies beneath it all?"--an interview study of GPs' attitudes to the use of guidelines. BMC Health Serv Res. 2008; 8:218. PMC: 2577651. DOI: 10.1186/1472-6963-8-218. View

15.

Gale N, Marshall T, Bramley G . Starting and staying on preventive medication for cardiovascular disease. Curr Opin Cardiol. 2012; 27(5):533-41. DOI: 10.1097/HCO.0b013e328356dae5. View

16.

Gale N, Greenfield S, Gill P, Gutridge K, Marshall T . Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study. BMC Fam Pract. 2011; 12:59. PMC: 3135546. DOI: 10.1186/1471-2296-12-59. View

17.

Ikeda N, Sapienza D, Guerrero R, Aekplakorn W, Naghavi M, Mokdad A . Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ. 2014; 92(1):10-19C. PMC: 3865548. DOI: 10.2471/BLT.13.121954. View

18.

Fung V, Graetz I, Reed M, Jaffe M . Patient-reported adherence to statin therapy, barriers to adherence, and perceptions of cardiovascular risk. PLoS One. 2018; 13(2):e0191817. PMC: 5805247. DOI: 10.1371/journal.pone.0191817. View

19.

Oriol-Zerbe C, Abholz H . Primary prevention of cardiovascular diseases by lipid-lowering treatment in German general practice: results from GPs ignoring guidelines and risk calculators. Eur J Gen Pract. 2007; 13(1):27-34. DOI: 10.1080/13814780601050541. View

20.

Thomas J, Harden A . Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008; 8:45. PMC: 2478656. DOI: 10.1186/1471-2288-8-45. View